Your browser is no longer supported. Please, upgrade your browser.
Settings
HALO Halozyme Therapeutics, Inc. daily Stock Chart
HALO [NASD]
Halozyme Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.91 Insider Own3.50% Shs Outstand142.41M Perf Week-12.55%
Market Cap1.82B Forward P/E- EPS next Y-0.81 Insider Trans0.00% Shs Float109.14M Perf Month-4.78%
Income-116.10M PEG- EPS next Q-0.25 Inst Own90.30% Short Float22.69% Perf Quarter5.63%
Sales133.80M P/S13.57 EPS this Y-216.50% Inst Trans3.52% Short Ratio18.93 Perf Half Y-0.62%
Book/sh-0.45 P/B- EPS next Y19.80% ROA-43.50% Target Price16.77 Perf Year36.80%
Cash/sh1.26 P/C10.14 EPS next 5Y55.00% ROE499.10% 52W Range7.70 - 15.20 Perf YTD29.05%
Dividend- P/FCF- EPS past 5Y-33.10% ROI-45.80% 52W High-16.12% Beta2.26
Dividend %- Quick Ratio3.40 Sales past 5Y21.20% Gross Margin75.30% 52W Low65.58% ATR0.55
Employees259 Current Ratio3.60 Sales Q/Q-30.40% Oper. Margin-70.70% RSI (14)37.52 Volatility4.21% 3.58%
OptionableYes Debt/Eq- EPS Q/Q-64.70% Profit Margin-86.80% Rel Volume1.06 Prev Close12.79
ShortableYes LT Debt/Eq- EarningsMay 09 AMC Payout- Avg Volume1.31M Price12.75
Recom2.30 SMA20-8.43% SMA50-6.03% SMA2007.35% Volume1,384,020 Change-0.31%
Jan-06-17Downgrade Citigroup Buy → Neutral
Nov-03-16Initiated Deutsche Bank Buy $12
Dec-04-15Initiated Wells Fargo Outperform
Nov-18-15Initiated Citigroup Buy
Sep-22-15Initiated Barclays Overweight $27
Jun-22-15Reiterated JP Morgan Overweight $20 → $25
Mar-03-15Reiterated UBS Buy $16 → $21
Feb-18-15Reiterated MLV & Co Buy $15 → $20
Jan-08-15Reiterated MLV & Co Buy $12 → $15
Dec-24-14Initiated MLV & Co Buy $12
Jun-12-14Upgrade UBS Neutral → Buy $14 → $16
Jan-10-14Reiterated Barclays Equal Weight $12 → $15
Nov-11-13Reiterated UBS Neutral $8 → $14
Nov-11-13Reiterated Barclays Equal Weight $8 → $12
Aug-02-13Downgrade Barclays Overweight → Equal Weight $9 → $8
May-01-13Reiterated UBS Neutral $8 → $6.50
Sep-24-12Reiterated Barclays Overweight $8 → $10
Oct-18-11Upgrade JMP Securities Mkt Perform → Mkt Outperform $9
Apr-01-11Initiated Stifel Nicolaus Buy $10
Oct-19-10Initiated JMP Securities Mkt Perform
May-22-17 08:38AM  Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : May 22, 2017 Capital Cube
May-19-17 04:55PM  Why Halozyme Therapeutics, Seadrill, and Sibanye Gold Slumped Today Motley Fool -8.83%
04:27PM  Halozyme Therapeutics, Inc.'s Necessary Move Sends Shares Down as Much as 10% Motley Fool
09:16AM  Biotech Movers: Lion Biotechnologies, XBiotech, Halozyme TheStreet.com
May-18-17 09:25PM  Halozyme Therapeutics Prices Public Offering Of Common Stock PR Newswire
04:49PM  Halozyme shares fall after secondary share offering annoucned MarketWatch
04:05PM  Halozyme Therapeutics Announces Public Offering Of Common Stock PR Newswire
08:15AM  Blog Coverage: Omeros' Stock Jumped on Completion of IgA nephropathy Cohort and Additional Positive Results Accesswire
May-17-17 05:29PM  Halozyme Phase 2 Data In Advanced Pancreas Cancer To Be Featured In An Oral Presentation At ASCO PR Newswire -5.62%
May-15-17 09:15AM  Edited Transcript of HALO earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-10-17 09:31PM  Edited Transcript of HALO earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-09-17 06:10PM  Halozyme Therapeutics reports 1Q loss Associated Press
04:05PM  Halozyme Reports First Quarter 2017 Financial Results PR Newswire
10:15AM  Investor Network: Halozyme Therapeutics, Inc. to Host Earnings Call Accesswire
Apr-24-17 03:24PM  Halozyme Therapeutics, Inc. Value Analysis (NASDAQ:HALO) : April 24, 2017 Capital Cube
Apr-21-17 08:47AM  Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : April 21, 2017 Capital Cube
Apr-20-17 06:22PM  If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss TheStreet.com
Apr-10-17 04:15PM  Halozyme To Host First Quarter 2017 Financial Results Conference Call PR Newswire
Apr-06-17 08:29AM  Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : April 6, 2017 Capital Cube
Apr-03-17 08:00AM  Halozyme's PEGPH20 Increases Immune Response and Effectiveness of Immunotherapies in Preclinical Cancer Models PR Newswire
Mar-31-17 09:30AM  Rosetta Genomics and Halozyme Therapeutics: Wait for Better News Accesswire
Mar-30-17 11:48AM  Here's Why Halozyme Therapeutics, Inc Is Falling Motley Fool -8.82%
09:54AM  Biotech Premarket Movers: Halozyme, Omeros, Aralez TheStreet.com
08:30AM  Halozyme Provides Update On SWOG Collaborative Group Clinical Study PR Newswire
Mar-29-17 08:32PM  ETFs with exposure to Halozyme Therapeutics, Inc. : March 30, 2017 Capital Cube
12:44PM  FDA Advisory Committee Provides Unanimous Recommendation For Subcutaneous Rituximab Coformulated With Halozyme Enhanze Technology PR Newswire
Mar-06-17 01:44PM  ETFs with exposure to Halozyme Therapeutics, Inc. : March 6, 2017
Mar-04-17 01:04PM  HALOZYME THERAPEUTICS INC Financials
Mar-02-17 10:38AM  Halozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017 Capital Cube
09:22AM  5 Small-Cap Biotech Stocks to Buy in March Motley Fool
Mar-01-17 04:03AM  Edited Transcript of HALO earnings conference call or presentation 28-Feb-17 9:30pm GMT
Feb-28-17 07:03PM  HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition
07:00PM  HALOZYME THERAPEUTICS INC Files SEC form 10-K, Annual Report
04:59PM  Halozyme Therapeutics reports 4Q loss
04:05PM  Halozyme Reports Fourth Quarter And Full Year 2016 Financial Results PR Newswire
07:07AM  Q4 2016 Halozyme Therapeutics Inc Earnings Release - After Market Close
Feb-27-17 08:44AM  Why Halozyme Therapeutics (HALO) Might Surprise This Earnings Season
Feb-23-17 04:30PM  Halozyme Therapeutics To Present At Upcoming Healthcare Conferences PR Newswire
Feb-13-17 08:30AM  MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 with Halozyme PEGPH20 PR Newswire
Feb-02-17 09:30AM  Why Halozyme Therapeutics, Inc. Jumped 15.6% in January at Motley Fool
Feb-01-17 04:30PM  Halozyme To Host Fourth Quarter 2016 Financial Results Conference Call PR Newswire
Jan-27-17 07:56AM  Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : January 27, 2017
Jan-26-17 04:28PM  5 Small-Cap Biotech Stocks to Buy in February at Motley Fool
Jan-17-17 12:02PM  ETFs with exposure to Halozyme Therapeutics, Inc. : January 17, 2017
Jan-16-17 08:17AM  Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : January 16, 2017
Jan-11-17 10:10AM  Halozyme Estimates 2017 Revenue of $115M to $130M at Investopedia -7.60%
07:45AM  Why trader is selling Halozyme calls
Jan-10-17 03:52PM  Here's Why Halozyme Therapeutics Fell as Much as 11.1% Today at Motley Fool -9.48%
09:02AM  HALOZYME THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:40AM  Halozyme Therapeutics (HALO) in Focus: Stock Up 6.4%
Jan-09-17 04:14PM  HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure +6.43%
04:05PM  Halozyme Provides Program Updates, 2017 Financial Guidance At 35th Annual JP Morgan Healthcare Conference PR Newswire
10:41AM  Can the Rally in Halozyme (HALO) Shares Continue?
09:30AM  Biotech Industry Off to a Strong Start in 2017 Latest Reports on Halozyme Therapeutics and Geron Accesswire
Jan-06-17 11:44AM  ETFs with exposure to Halozyme Therapeutics, Inc. : January 6, 2017 +6.11%
11:25AM  Why Halozyme Therapeutics, Inc Fell 40.6% in 2016 at Motley Fool
10:10AM  Company News for January 06, 2017
09:45AM  Halozyme Pancreatic Cancer Drug Succeeds in Trial at Investopedia
08:30AM  Halozyme Therapeutics (HALO) Worth a Look: Stock Up 18%
08:19AM  Halozyme (HALO) Up on Positive Phase II Data on PEGPH20
07:58AM  Halozyme Therapeutics downgraded by Citigroup
07:39AM  Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : January 6, 2017
06:00AM  Constellation Brands, Halozyme Therapeutics: Jim Cramer's Top Takeaways
Jan-05-17 07:35PM  Retail, Politics and Bonds Signal Trend Changes: Cramer's 'Mad Money' Recap (Thursday 1/5/17) +17.96%
07:09PM  Shares of Halozyme spike 17% after positive results for pancreatic cancer drug at CNBC
05:33PM  Why Barrick Gold, Halozyme Therapeutics, and CEB Jumped Today at Motley Fool
04:51PM  3 ideas to improve waiting for your trades
04:50PM  Macy's and Toyota skid; Sears jumps
11:40AM  Why These 5 Biopharma Stocks Are Making Massive Gains on Thursday
11:25AM  Why Halozyme Therapeutics, Inc Is Rising Today at Motley Fool
11:13AM  #1 issue top traders want to fix in 2017 on our prop desk
07:19AM  HALOZYME THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Halozyme Announces Phase 2 Study In Advanced Pancreas Cancer Meets Key Endpoints PR Newswire
Dec-22-16 04:30PM  Halozyme Therapeutics To Present At The 35th Annual J.P. Morgan Healthcare Conference PR Newswire -5.19%
Dec-19-16 04:07PM  HALOZYME THERAPEUTICS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financ
Dec-16-16 10:31AM  Halozyme Therapeutics, Inc. Value Analysis (NASDAQ:HALO) : December 16, 2016
Dec-15-16 07:45AM  Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : December 15, 2016
Dec-09-16 05:03PM  Is Halozyme Therapeutics, Inc. (HALO) Worthy of Your Portfolio? at Insider Monkey
Dec-05-16 12:33PM  Why Halozyme Therapeutics, Inc. Stock Soared 39.6% in November at Motley Fool
Nov-22-16 09:55AM  AbbVie Nixes Halozyme Drug Partnership (HALO, ABBV) at Investopedia
Nov-21-16 03:25PM  Abbvie Ends Development Program With Halozyme
08:30AM  Halozyme Provides Update On AbbVie Collaboration PR Newswire
Nov-16-16 01:10PM  ETFs with exposure to Halozyme Therapeutics, Inc. : November 16, 2016 -8.71%
Nov-15-16 10:43AM  Halozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q3, 2016 By the Numbers : November 15, 2016
Nov-11-16 07:09AM  Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : November 11, 2016
Nov-10-16 08:30AM  Halozyme Announces Broad Clinical Collaboration Agreement To Evaluate PEGPH20 And Tecentriq In Up To Eight Tumor Types PR Newswire +6.39%
06:36AM  Here's Why These Biopharma Stocks Soared at Least 10% Today at Motley Fool
Nov-09-16 12:13PM  Halozyme 3Q Loss $29M, or 23 Cents a Share (HALO) at Investopedia +18.22%
Nov-08-16 05:49PM  Why Did Halozyme Therapeutics, Inc. Plunge 29.5% in October? at Motley Fool +8.91%
04:14AM  Edited Transcript of HALO earnings conference call or presentation 7-Nov-16 9:30pm GMT
Nov-07-16 05:46PM  Halozyme Therapeutics reports 3Q loss
04:22PM  HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition
04:05PM  Halozyme Reports Third Quarter 2016 Financial Results PR Newswire
07:07AM  Q3 2016 Halozyme Therapeutics Inc Earnings Release - After Market Close
Nov-03-16 08:30AM  FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab PR Newswire
Oct-28-16 01:17PM  First Eagle Fund of America 3rd Quarter Commentary
Oct-18-16 10:28AM  ETFs with exposure to Halozyme Therapeutics, Inc. : October 18, 2016
Oct-13-16 04:30PM  Halozyme To Host Third Quarter 2016 Financial Results Conference Call PR Newswire
08:26AM  Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : October 13, 2016
Oct-11-16 04:31PM  Supernus Stock Reverses Downward Despite Good ADHD Drug Trial
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, and metastatic breast cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; and Genentech. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KIRK RANDAL JDirectorMay 11Option Exercise10.3710,000103,7003,562,388May 15 09:09 AM
MATSUI CONNIEDirectorMay 08Option Exercise10.3710,000103,700247,388May 09 06:00 PM
LEONHARDT HARRY JSVP, GC and CCOApr 13Option Exercise0.006,875020,382Apr 14 02:03 PM
Torley HelenPresident and CEOFeb 06Option Exercise0.0031,2500244,159Feb 07 04:39 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 03Option Exercise0.0023,120029,995Feb 06 07:01 PM
Countouriotis AthenaSVP and Chief Medical OfficerFeb 03Option Exercise0.0018,496045,977Feb 06 07:01 PM
LEONHARDT HARRY JSVP, GC and CCOFeb 03Option Exercise0.0015,413019,705Feb 06 07:01 PM
Torley HelenPresident and CEOFeb 03Option Exercise0.0055,4870212,909Feb 06 07:00 PM
Torley HelenPresident and CEOJan 06Option Exercise0.0030,0000157,422Jan 09 04:04 PM
Countouriotis AthenaSVP and Chief Medical OfficerJan 05Option Exercise0.007,500027,481Jan 09 04:03 PM
Countouriotis AthenaSVP and Chief Medical OfficerJun 30Option Exercise0.006,450020,088Jul 05 04:55 PM
Torley HelenPresident and CEOJun 30Option Exercise0.0013,5000134,466Jul 05 04:53 PM
Stelzer LaurieSVP, Chief Financial OfficerJun 15Option Exercise0.006,875016,875Jun 16 04:12 PM